

CITATION REPORT

List of articles citing

Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Ments Issue?

DOI: 10.1007/s11906-019-0924-0
Current Hypertension Reports, 2019, 21, 22.

Source: <https://exaly.com/paper-pdf/73451833/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 16 | Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. <i>Heart Failure Reviews</i> , 2019 , 24, 847-866 | 5 | 11 |
| 15 | Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. <i>Vascular Health and Risk Management</i> , 2019 , 15, 571-579 | 4.4 | 3 |
| 14 | Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e21694 | 1.8 | 3 |
| 13 | 2020 International Society of Hypertension Global Hypertension Practice Guidelines. <i>Hypertension</i> , 2020 , 75, 1334-1357 | 8.5 | 628 |
| 12 | 2020 International Society of Hypertension global hypertension practice guidelines. <i>Journal of Hypertension</i> , 2020 , 38, 982-1004 | 1.9 | 158 |
| 11 | The Road to Better Management in Resistant Hypertension-Diagnostic and Therapeutic Insights. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 0 |
| 10 | Treatment of Resistant Hypertension in Real Clinical Settings. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 200-205 | 0.5 | |
| 9 | Effects of Spironolactone on Hypoxia-Inducible Factor-1 α in the Patients Receiving Coronary Artery Bypass Grafting. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, e101-e104 | 3.1 | |
| 8 | Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 724-735 | 2.6 | 0 |
| 7 | Pharmacoepidemiology in Cardiorenal Medicine. 2021 , 315-331 | | |
| 6 | Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.. <i>PLoS ONE</i> , 2022 , 17, e0265642 | 3.7 | 2 |
| 5 | Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. <i>Consilium Medicum</i> , 2022 , 24, 28-35 | 1.9 | |
| 4 | Real-world implementation of guidelines for heart failure management: A systematic review and meta-analysis.. <i>Hellenic Journal of Cardiology</i> , 2022 , | 2.1 | |
| 3 | Identifying and managing adverse drug reactions to promote medicines adherence and safety. <i>Nursing Standard (Royal College of Nursing (Great Britain): 1987)</i> , 2022 , 37, 60-66 | 1.1 | |
| 2 | Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone. 2022 , 6, e791 | | 0 |
| 1 | The Idiosyncratic Efficacy of Spironolactone-Loaded PLGA Nanoparticles Against Murine Intestinal Schistosomiasis. Volume 18, 987-1005 | | 0 |